Statistik Asas
| LEI | 3358002FLK8AK8WSEP31 |
| CIK | 1730430 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kiniksa Pharmaceuticals, Ltd.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-730430 98-1795578 (State or other jurisdictio |
|
| September 3, 2025 |
Exhibit 99.1 Corporate Presentation SEPTEMBER 2025 Forward Looking Statements 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements with respect to Kiniksa Pharmaceuticals International, plc (and its consolidated subsidiaries, collectively, unless context otherwise requires, “Kiniksa,” “we,” “us” or “our” |
|
| July 29, 2025 |
2018 Incentive Award Plan and forms of award agreements thereunder, as amended Exhibit 10.9 As Amended June 11, 2025 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 INCENTIVE AWARD PLAN (FORMERLY, KINIKSA PHARMACEUTICALS, LTD. 2018 INCENTIVE AWARD PLAN) ARTICLE I PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with eq |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-730430 98-1795578 (State or other jurisdiction of |
|
| July 29, 2025 |
Consulting Agreement by and between Kiniksa Pharmaceuticals International, plc and Dr. Richard Levy Exhibit 10.8 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(a)(6) CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made as of July 1, 2025 (the “Effective Date”) by and between Kiniksa Pharmaceuticals, GmbH a Swiss limited liability company with a business address at Grafenaustrasse 5, 6300 Zug, Switzerland (“Kiniksa”), and Dr. |
|
| July 29, 2025 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $625 - $640 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated; Phase 2 data expected |
|
| June 5, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-730430 98-1795578 (State or other jurisdiction of |
|
| June 5, 2025 |
Corporate Presentation JUNE 2025 Exhibit 99.2 Corporate Presentation JUNE 2025 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forward - looking statements with respect to Kiniksa Pharmaceuticals International, plc (and its consolidated subsidiaries, collectively, unless context otherwise requires, “Kiniksa,” “we,” “us” or “our”). In some cases, you can iden |
|
| June 5, 2025 |
Exhibit 99.1 Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis – KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – KPL-387 Phase 1 single ascending dose data support profile for monthly dosing – – Presentation and webcast at Jefferies 2025 Global Healthcare Conference scheduled for 12 |
|
| June 3, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-730430 98-1795578 (State or other jurisdiction of |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-730430 98-1795578 (State or other jurisdiction o |
|
| April 29, 2025 |
Form of 2025 Performance Share Unit Grant Notice and 2025 Performance Share Unit Award Agreement Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 INCENTIVE AWARD PLAN PERFORMANCE-BASED RESTRICTED SHARE UNIT GRANT NOTICE Capitalized terms not specifical |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 29, 2025 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $590 - $605 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; |
|
| April 23, 2025 |
Form of Milestone 2 Cash Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan Exhibit 10.3 LTIP – FDA Approval Milestone Cash Award KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 INCENTIVE AWARD PLAN PERFORMANCE CASH AWARD Grant Notice – FDA APPROVAL MILESTONE Capitalized terms not specifically defined in this Performance Cash Award Grant Notice (the “Grant Notice”) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to time, the “Plan”) |
|
| April 23, 2025 |
Exhibit 10.7 LTIP – FDA Approval Milestone Option Award KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 INCENTIVE AWARD PLAN SHARE OPTION GRANT NOTICE – FDA APPROVAL MILESTONE Capitalized terms not specifically defined in this Share Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to time, the “Plan”) or the KPL-387 Lon |
|
| April 23, 2025 |
Form of Milestone 1 PSU Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan Exhibit 10.4 LTIP – BLA Filing Milestone RSU Award KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED SHARE Unit Grant Notice – BLA FILING MILESTONE Capitalized terms not specifically defined in this Performance Restricted Share Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to t |
|
| April 23, 2025 |
Form of Milestone 1 Cash Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan Exhibit 10.2 LTIP – BLA Filing Milestone Cash Award KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 INCENTIVE AWARD PLAN PERFORMANCE CASH AWARD Grant Notice – BLA FILING MILESTONE Capitalized terms not specifically defined in this Performance Cash Award Grant Notice (the “Grant Notice”) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to time, the “Plan”) or t |
|
| April 23, 2025 |
Exhibit 10.6 LTIP – BLA Filing Milestone Option Award KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 INCENTIVE AWARD PLAN SHARE OPTION GRANT NOTICE – BLA FILING MILESTONE Capitalized terms not specifically defined in this Share Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to time, the “Plan”) or the KPL-387 Long-Te |
|
| April 23, 2025 |
Form of Milestone 2 PSU Award Grant Notice and Agreement under the KPL-387 Long-Term Incentive Plan Exhibit 10.5 LTIP – FDA Approval Milestone RSU Award KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED SHARE Unit Grant Notice – FDA APPROVAL MILESTone Capitalized terms not specifically defined in this Performance Restricted Share Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time |
|
| April 23, 2025 |
KPL-387 Long-Term Incentive Plan for Executive Officers Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Kiniksa Pharmaceuticals International, plc KPL-387 Long-Term Incentive Plan (VP+ Employees – Executive Officers) Effective Date: April 17, 2025 1. |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-730430 98-1795578 (State or other jurisdiction o |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 21, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 10, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| February 25, 2025 |
Exhibit 10.22 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is effective as of January 1, 2025 (the “Effective Date”), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the “Company”), and John Paolini (the “Employee”). WHEREAS, the operations of the Company and its Affiliates (as defined below) are a complex matter requiring direction and leadership in a va |
|
| February 25, 2025 |
As filed with the Securities and Exchange Commission on February 25, 2025 As filed with the Securities and Exchange Commission on February 25, 2025 Registration No. |
|
| February 25, 2025 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to i |
|
| February 25, 2025 |
Consulting Agreement by and between Kiniksa Pharmaceuticals International, plc and Dr. Richard Levy Exhibit 10.27 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(a)(6) CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made as of November 7, 2024 (the “Effective Date”) by and between Kiniksa Pharmaceuticals International, plc, a company incorporated in England and Wales with a business address at 23 Old Bond Street, Floor 3, Lond |
|
| February 25, 2025 |
Non-Employee Director Compensation Program Exhibit 10.40 Kiniksa Pharmaceuticals International, plc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Kiniksa Pharmaceuticals International, plc (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended, this “Program”). The cash and equity compensation descri |
|
| February 25, 2025 |
Exhibit 10.25 CHANGE IN CONTROL AGREEMENT This Change in Control Agreement (this “Agreement”) is made and entered into as of January 1, 2025 (the “Effective Date”), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Michael Megna (the “Employee”). WHEREAS, the Company recognizes that the possibility of a change in control of the Parent and a related involunta |
|
| February 25, 2025 |
Exhibit 10.26 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is effective as of January 1, 2025 (the “Effective Date”), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Ross Moat (the “Employee”). WHEREAS, the operations of the Company and its Affiliates (as defined below) are a complex matter requiring direction and leadership in a varie |
|
| February 25, 2025 |
Exhibit 10.24 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is effective as of January 1, 2025 (the “Effective Date”), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Eben Tessari (the “Employee”). WHEREAS, the operations of the Company and its Affiliates (as defined below) are a complex matter requiring direction and leadership in a va |
|
| February 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Kiniksa Pharmaceuticals International, plc (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A ordinary shares, nominal value $0. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2025 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-730430 98-1795578 (State or other jurisdictio |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 25, 2025 |
Employment Agreement, effective as of January 1, 2025, by and between the Company and Mark Ragosa Exhibit 10.23 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is effective as of January 1, 2025 (the “Effective Date”), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Mark Ragosa (the “Employee”). WHEREAS, the operations of the Company and its Affiliates (as defined below) are a complex matter requiring direction and leadership in a var |
|
| January 13, 2025 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance – ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – – Kiniksa expects to remain cash flow positive on an annual basis – LONDON |
|
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-730430 98-1795578 (State or other jurisdiction |
|
| November 14, 2024 |
SC 13G/A 1 p24-3179sc13ga.htm KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Kiniksa Pharmaceuticals International, plc (f/k/a Kiniksa Pharmaceuticals, Ltd.)** (Name of Issuer) Class A Ordinary Shares, $0.000273235 nominal value (Title of Class of Securities) G52694109 |
|
| November 14, 2024 |
KNSA / Kiniksa Pharmaceuticals, Ltd. / Fairmount Funds Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427721d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kiniksa Pharmaceuticals International, plc (f/k/a Kiniksa Pharmaceuticals, Ltd.)** (Name of Issuer) Class A Ordinary Shares, nominal value $0.000273235 (Title of Class of Securities) G52694109** (CUSIP Number) Se |
|
| November 13, 2024 |
KNSA / Kiniksa Pharmaceuticals, Ltd. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427812d9sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) (Name of Issuer) Class A Ordinary Shares, $0.000273235 par value per share (Title of Class of Securities) G52694109 (CUSIP Number) |
|
| October 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-730430 98-1795578 (State or other jurisdiction |
|
| October 29, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of August 1, 2024 (the “Effective Date”), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Ross Moat (the “Employee”). WHEREAS, the operations of the Company and its Affiliates (as defined below) are a complex matter requiring direction and leadership |
|
| October 29, 2024 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – – Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnershi |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 8, 2024 |
KNSA / Kiniksa Pharmaceuticals, Ltd. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SC 13D/A 1 tm2425843d1sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* Kiniksa Pharmaceuticals International, plc (f/k/a Kiniksa Pharmaceuticals, Ltd.)** (Name of Issuer) Class A Ordinary Shares, no |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 (October 4, 2024) Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-38492 98-1795578 (State or ot |
|
| July 25, 2024 |
Exhibit 10.12 MASTER SERVICES AGREEMENT between SAMSUNG BIOLOGICS CO., LTD. and KINIKSA PHARMACEUTICALS (UK), LTD. [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Table of Contents SECTION 1 DEFINITIONS 3 SECTION 2 |
|
| July 25, 2024 |
Exhibit 10.13 SAMSUNG BIOLOGICS CO., LTD. PRODUCT SPECIFIC AGREEMENT – COMMERCIAL PRODUCT DRUG SUBSTANCE This Product Specific Agreement (this “PSA”) is made effective as of June 21, 2024 (the “PSA Effective Date”) by and between Kiniksa Pharmaceuticals (UK), Ltd., a private company organized under the laws of England and Wales with a Swiss branch office located at Grafenaustrasse 5, 6300 Zug, Swi |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 23, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-38492 Applied For (State or other jurisdiction of |
|
| July 23, 2024 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $405 - $415 million – – Abiprubart clinical development fully funded; Phase 2b clinical trial in Sjögren’s Disease |
|
| July 23, 2024 |
15-15D/A 1 tm2419915d21515da.htm 15-15D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15/A (Amendment No. 1) CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 333-264746 KINIKS |
|
| July 2, 2024 |
T: (781) 431-9100 23 Old Bond St. London, UK W1S 4PZ July 2, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 28, 2024 |
Exhibit 10.10 AGREEMENT DATED JUNE 28, 2024 COMPUTERSHARE Trust COMPANY, N.A. KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC and Holders of Depositary Receipts Agreement for the provision of depositary services and custody services in respect of KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC a Depositary Receipts and A1 DEPOSITARY RECEIPTS CONTENTS Section Page 1. Definitions and Interpretation 3 2. Appoi |
|
| June 28, 2024 |
Offering document under the 2018 Employee Share Purchase Plan Exhibit 10.9 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 EMPLOYEE SHARE PURCHASE PLAN (Formerly, KINIKSA PHARMACEUTICALS, LTD. 2018 EMPLOYEE SHARE PURCHASE PLAN) OFFERING DOCUMENT This document (this “Offering Document”) was adopted by the Compensation Committee of the Board of Directors of Kiniksa Pharmaceuticals, Ltd., predecessor of Kiniksa Pharmaceuticals International, plc (the “Company”) |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
2018 Incentive Award Plan and forms of award agreement thereunder Exhibit 10.4 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 INCENTIVE AWARD PLAN (FORMERLY, KINIKSA PHARMACEUTICALS, LTD. 2018 INCENTIVE AWARD PLAN) ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportuni |
|
| June 28, 2024 |
2018 Incentive Award Plan; Sub-Plan for UK Employees and forms of award agreement thereunder Exhibit 10.5 Kiniksa Pharmaceuticals International, PLC 2018 INCENTIVE AWARD PLAN SUB-PLAN FOR UK EMPLOYEES 1. Purpose Pursuant to the powers granted by the Administrator in Section 10.5 of the Kiniksa Pharmaceuticals International, plc 2018 Incentive Award Plan (as it may be amended or restated from time to time, the “Plan”), the Administrator has adopted this Sub-Plan (as amended and |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
Form of Indemnification Agreement for Directors Exhibit 10.1 Dated [DAY MONTH YEAR] Between KINIKSA PHARMACEUTICALS LTD., as Company with [name] as Indemnitee INDEMNIFICATION AGREEMENT TABLE OF CONTENTS Page 1. Indemnity of Indemnitee 2 2. Additional Indemnity 3 3. Contribution 3 4. Indemnification for Expenses of a Witness 4 5. Advancement of Expenses 4 6. Procedures and Presumptions for Determination of Entitlement to INDEMNIFICATION 5 7. Rem |
|
| June 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Kiniksa Pharmaceuticals International, plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(3) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Unallocated (Universal Shelf) (1) 457(o) $400,000,000 N/A $400,000,000 0. |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K12B CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2024 (June 27, 2024) Kiniksa Pharmaceuticals International, plc (Exact Name of Registrant as Specified in Charter) England and Wales 001-38492 Applied For (State or other |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
As filed with the United States Securities and Exchange Commission on June 27, 2024 As filed with the United States Securities and Exchange Commission on June 27, 2024 Registration No. |
|
| June 28, 2024 |
Exhibit 10.11 AGREEMENT DATED june 28, 2024 COMPUTERSHARE Trust COMPANY, N.A. KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC and Holders of Depositary Receipts Agreement for the provision of depositary services and custody services in respect of KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC B Depositary Receipts and B1 DEPOSITARY RECEIPTS CONTENTS Section Page 1. Definitions and Interpretation 1 2. Appoi |
|
| June 28, 2024 |
Exhibit 10.7 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 INCENTIVE AWARD PLAN SHARE OPTION GRANT NOTICE FOR SWISS PARTICIPANTS Capitalized terms not specifically defined in this Share Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to time, the “Plan”) of Kiniksa Pharmaceuticals International, plc (the “Company”). |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
Exhibit 4.3 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1. Issuable in Series 5 Secti |
|
| June 28, 2024 |
Exhibit 10.6 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC 2018 INCENTIVE AWARD PLAN SHARE OPTION GRANT NOTICE FOR GERMAN PARTICIPANTS Capitalized terms not specifically defined in this Share Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to time, the “Plan”) of Kiniksa Pharmaceuticals International, plc (the “Company”). |
|
| June 28, 2024 |
2018 Employee Share Purchase Plan Exhibit 10.8 Kiniksa Pharmaceuticals International, PLC 2018 EMPLOYEE SHARE PURCHASE PLAN (FORMERLY, KINIKSA PHARMACEUTICALS, LTD. 2018 EMPLOYEE SHARE PURCHASE PLAN) ARTICLE I. PURPOSE The purposes of this Kiniksa Pharmaceuticals International, plc 2018 Employee Share Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of Kiniksa Pharmace |
|
| June 28, 2024 |
Specimen Share Certificate evidencing Class A Ordinary Shares Exhibit 4.1 THIS CERTIFIES THAT is the owner of DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY-PAID SHARES OF A ORDINARY SHARES OF Kiniksa Pharmaceuticals International, plc (hereinafter called the “Company”) transferable in accordance with, and subject to, the Company’s articles of association on the books of the Company in person or by d |
|
| June 28, 2024 |
Articles of Association of Kiniksa Pharmaceuticals International, plc Exhibit 3.1 The Companies Acts Public Company Limited by Shares ARTICLES OF ASSOCIATION Of KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC (Adopted by special resolution passed on 27 June 2024) TABLE OF CONTENTS DEFINITIONS AND INTERPRETATION 1 1. Definitions and interpretation 1 2. Limited liability 5 3. Exclusion of the Model Articles and Statutes 5 4. Form of resolutions 5 SHARE CAPITAL 6 5. Rights |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
Exhibit 10.3 Kiniksa Pharmaceuticals International, PLC 2015 EQUITY INCENTIVE PLAN (FORMERLY, KINIKSA PHARMACEUTICALS, LTD. 2015 EQUITY INCENTIVE PLAN) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Kiniksa Pharmaceuticals International, plc 2015 Equity Incentive Plan, have the following meanings: Administrator means the Bo |
|
| June 28, 2024 |
Form of Indemnification Agreement for Officers Exhibit 10.2 Dated [DAY MONTH YEAR] Between KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC as Company and [NAME] as Indemnitee INDEMNIFICATION AGREEMENT TABLE OF CONTENTS Page 1. Indemnity of Indemnitee 1 2. Additional Indemnity 2 3. Contribution 3 4. Indemnification for Expenses of a Witness 4 5. Advancement of Expenses 4 6. Procedures and Presumptions for Determination of Entitlement to Indemnificat |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 333-264746 KINIKSA PHARMACEUTICALS, LTD.* (Exact name of registrant as specifie |
|
| June 28, 2024 |
Exhibit 4.2 DESCRIPTION OF SHARE CAPITAL The following description of our share capital is not complete and may not contain all the information you should consider before investing in our securities. This description is summarized from, and qualified in its entirety by reference to, our articles of association which have been publicly filed with the SEC. Share Capital Under the U.K. Companies Act |
|
| June 25, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or organ |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-38492 98-1327726 (State or other jurisdiction of incorporation) (Commiss |
|
| June 5, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-38492 98-1327726 (State or other jurisdiction of incorporation) (Commissi |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 25, 2024 |
Consulting Agreement by and between Kiniksa Pharmaceuticals, Ltd. and Dr. Richard Levy Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(a)(6) CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made as of November 3, 2023 (the “Effective Date”) by and between Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company with a business address at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (“Kini |
|
| April 25, 2024 |
Form of 2024 Performance Share Unit Grant Notice and 2024 Performance Share Unit Award Agreement Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. KINIKSA PHARMACEUTICALS, LTD. 2018 INCENTIVE AWARD PLAN PERFORMANCE-BASED RESTRICTED SHARE UNIT GRANT NOTICE Capitalized terms not specifically defined in |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 23, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 23, 2024 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $370 - $390 million – – Abiprubart Phase 2b trial in Sjögren’s Disease planned to initiate in 2H 2024 – – Current ope |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or orga |
|
| April 10, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 2, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or organ |
|
| April 2, 2024 |
Exhibit 99.1 Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart – Abiprubart Phase 2b trial in Sjogren’s Disease planned to initiate in 2H 2024 – – Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity – – Abiprubart development in Sjogren’s Disease fully funded through Phase 3 – – Company expects to remain cash flow positive on an annual b |
|
| April 2, 2024 |
Exhibit 99.2 Corporate Presentation APRIL 2024 Forward Looking Statements 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiaries, collectively, unless context otherwise requires, “Kiniksa,” “we,” “us” or “our”). In some cases, |
|
| March 29, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2024 Kiniksa Pharmaceuticals, Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation) (Comm |
|
| March 29, 2024 |
Practice Statement Letter dated as of March 29, 2024 Exhibit 99.1 From: Kiniksa Pharmaceuticals, Ltd. To: The holders of common shares of the Company March 29, 2024 Dear Shareholder, PRACTICE STATEMENT LETTER PROPOSED SCHEME OF ARRANGEMENT IN RESPECT OF: KINIKSA PHARMACEUTICALS, LTD. This letter (the “Practice Statement Letter”) concerns matters which may affect your legal rights and entitlements and you may therefore wish to take appropriate legal |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confiden |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2024 Kiniksa Pharmaceuticals, Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation) (Comm |
|
| March 29, 2024 |
T: +1 (781) 431-9100 Clarendon House 2 Church Street Hamilton HM11, Bermuda Exhibit 99.1 From: Kiniksa Pharmaceuticals, Ltd. To: The holders of common shares of the Company March 29, 2024 Dear Shareholder, PRACTICE STATEMENT LETTER PROPOSED SCHEME OF ARRANGEMENT IN RESPECT OF: KINIKSA PHARMACEUTICALS, LTD. This letter (the “Practice Statement Letter”) concerns matters which may affect your legal rights and entitlements and you may therefore wish to take appropriate legal |
|
| February 28, 2024 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue expected to be $360 - $380 million, representing ~59% year-over-year growth at the midpoint – – Abiprubart Phase |
|
| February 28, 2024 |
Exhibit 10.36 KINIKSA PHARMACEUTICALS, LTD. 2018 INCENTIVE AWARD PLAN SHARE OPTION GRANT NOTICE FOR SWISS PARTICIPANTS Capitalized terms not specifically defined in this Share Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to time, the “Plan”) of Kiniksa Pharmaceuticals, Ltd. (the “Company”). The Company has granted t |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or o |
|
| February 28, 2024 |
Insider Trading Compliance Program Exhibit 19.1 INSIDER TRADING COMPLIANCE POLICY POL-0029 1. Purpose This global policy describes Kiniksa Pharmaceuticals’ (“Kiniksa” or “Company”) requirements for the prevention of insider trading. Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of the Company as well as that of all persons affiliated with the Company. Insider tra |
|
| February 28, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables S-8 (Form Type) Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common shares, par val |
|
| February 28, 2024 |
Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 KINIKSA PHARMACEUTICALS, LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION POL-0066 1. Effective Date Kiniksa Pharmaceuticals, Ltd. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 14, 2024 |
KNSA / Kiniksa Pharmaceuticals, Ltd. / Fairmount Funds Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245759d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kiniksa Pharmaceuticals, Ltd. (Name of Issuer) Class A Common Shares, par value $0.000273235 (Title of Class of Securities) G5269C101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This S |
|
| February 14, 2024 |
SC 13G/A 1 p24-0563sc13ga.htm KINIKSA PHARMACEUTICALS, LTD. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Kiniksa Pharmaceuticals, Ltd. (Name of Issuer) Class A Common Shares, par value $0.000273235 per share (Title of Class of Securities) G5269C101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires |
|
| February 13, 2024 |
KNSA / Kiniksa Pharmaceuticals, Ltd. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01282-kiniksapharmaceutica.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Kiniksa Pharmaceuticals Ltd. Class A Title of Class of Securities: Common Stock CUSIP Number: G5269C101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appro |
|
| February 12, 2024 |
KNSA / Kiniksa Pharmaceuticals, Ltd. / Rubric Capital Management LP - SC 13G Passive Investment SC 13G 1 tm245464d9sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kiniksa Pharmaceuticals, Ltd. (Name of Issuer) Class A Common Shares, $0.000273235 par value per share (Title of Class of Securities) G5269C101 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or org |
|
| January 4, 2024 |
Corporate Presentation JANUARY 2024 Exhibit 99.2 Corporate Presentation JANUARY 2024 Forward Looking Statements 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forwar d - l ooking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiaries, collectively, u |
|
| January 4, 2024 |
Exhibit 99.1 Kiniksa Pharmaceuticals Provides Corporate Update – ARCALYST® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) – – ARCALYST 2024 net product revenue expected to be $360 - $380 million – – Abiprubart (KPL-404) Phase 2 rheumatoid arthritis trial met the primary efficacy endpoint in Cohort 3 at the weekly dose level – – Abiprubart Phase 2 rheum |
|
| December 8, 2023 |
December 8, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Frank Wyman & Ibolya Ignat FOIA Confidential Treatment Request Confidential Treatment Requested by Kiniksa Pharmaceuticals, Ltd. under 17 C.F.R. § 200.83 Re: Kiniksa Pharmaceuticals, Ltd. Form 10-K for the fiscal year ended |
|
| November 21, 2023 |
ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM November 21, 2023 Frank Wyman Ibolya Ignat Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-9303 Re: Kiniksa Pharmaceuticals, Ltd. Form 10-K for the fiscal year ended December 31, 2022 Filed March 2, 2023 File No. 001-3849 |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 31, 2023 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth – – KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in Q1 2024 – – Cash reserves of $201 million expected to fund operations into at least 2027 – – Conf |
|
| October 31, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or or |
|
| August 18, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Kiniksa Pharmaceuticals, Ltd. (Name of Issuer) Class A Common Shares, par value $0.000273235 per share (Title of Class of Securities) G5269C101 (CUSIP Number) December 31, 2022** (Date of Event Which Requires Filing of This Statement) Check the appropriate box to de |
|
| August 18, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p23-2095exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kiniksa Pharmaceuticals, Ltd. (Name of Issuer) Class A Common Shares, par value $0.000273235 (Title of Class of Securities) G5269C101 (CUSIP Number) August 2, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to design |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 1, 2023 |
Exhibit 10.1 SIXTH AMENDMENT OF SUBLEASE SIXTH AMENDMENT OF SUBLEASE (the “Sixth Sublease Amendment”) made as of the 24th day of May, 2023, by and between 92 HAYDEN AVENUE TRUST, as landlord (“Landlord”), and KINIKSA PHARMACEUTICALS CORP., a Delaware corporation, as tenant (interchangeably called “Kiniksa” or “Tenant”). RECITALS WHEREAS, by Lease dated May 22, 2008, as amended by First Amendment t |
|
| July 25, 2023 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q2 2023 net product revenue of $54.5 million – – ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the midpoint – – KPL-404 Phase 2 rheumatoid arthritis data expected in 1H 2024 – – Cash rese |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or organ |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 (June 6, 2023) Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-38492 98-1327726 (State or other jurisdiction of incorpora |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or organiz |
|
| May 2, 2023 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q1 2023 net product revenue of $42.7 million – – ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growth at the midpoint – – Final cohort of KPL-404 Phase 2 rheumatoid arthritis trial now enr |
|
| April 27, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or orga |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| March 2, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables S-8 (Form Type) Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common shares, par val |
|
| February 28, 2023 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively – – ARCALYST full-year 2023 net product revenue expected to be $190 - $205 million, representing >60% year-over-year growth at the midpoint – – ARCALY |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or o |
|
| February 14, 2023 |
SC 13G/A 1 p23-0179sc13ga.htm KINIKSA PHARMACEUTICALS, LTD. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Kiniksa Pharmaceuticals, Ltd. (Name of Issuer) Class A Common Shares, par value $0.000273235 per share (Title of Class of Securities) G5269C101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires |
|
| February 9, 2023 |
KNSA / Kiniksa Pharmaceuticals Ltd / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Kiniksa Pharmaceuticals Ltd. Class A Title of Class of Securities: Common Stock CUSIP Number: G5269C101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 3, 2023 |
KNSA / Kiniksa Pharmaceuticals Ltd / PICTET ASSET MANAGEMENT SA - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kiniksa Pharmaceuticals Ltd (Name of Issuer) COMMON STOCK (Title of Class of Securities) G5269C101 (CUSIP Number) 12/31/2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| January 9, 2023 |
Exhibit 99.1 Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update – ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively (unaudited) – – 2 of 3 cohorts enrolled in KPL-404 Phase 2 trial in rheumatoid arthritis; data expected in 1H 2024 – – Cash reserves expected to fund operations into at least 2025 – HAMILTON, BERMUDA – |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or org |
|
| November 3, 2022 |
Exhibit 10.1 ? License Agreement ? This License Agreement is entered as of the Execution Date (as defined below), with certain provisions that go into effect as of the Effective Date (as defined below), by and between Genentech, Inc. with an office and place of business at 1 DNA Way, South San Francisco, California 94080, (?Genentech?); ? and ? F. Hoffmann-La Roche Ltd with an office and place of |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 3, 2022 |
FIFTH AMENDMENT OF SUBLEASE ? ? FIFTH AMENDMENT OF SUBLEASE (the "Fifth Sublease Amendment") made as of the 27th day of July, 2022, by and between 92 HAYDEN AVENUE TRUST, as landlord ("Landlord"), and KINIKSA PHARMACEUTICALS CORP. |
|
| November 3, 2022 |
CONFIDENTIAL [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv). |
|
| November 1, 2022 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update ? ARCALYST? (rilonacept) Q3 2022 net revenue of $33.4 million ? ? RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard Ratio = 0.018, p<0.0001) ? ? KPL-404 Phase 2 data in rheumatoid arthritis expected in 1H |
|
| November 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or or |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 (August 2, 2022) Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-38492 98-1327726 (State or other jurisdiction of incor |
|
| August 3, 2022 |
Exhibit 99.2 Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab – Kiniksa to receive $100 million in upfront and near-term payments – – Kiniksa is eligible to receive development and commercial milestones as well as royalties on net sales – – Global license includes development and commercialization rights to vixarelimab – HAMILTON, BERMUDA – August 3, 2022 – |
|
| August 3, 2022 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update – ARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Upfront and near-term proceeds of $100 million expected from vixarelimab global license agreement – – Cash reserves after the close of the vixa |
|
| June 30, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2022 (June 29, 2022) Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-38492 98-1327726 (State or other jurisdiction of incorpo |
|
| May 13, 2022 |
May 13, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 13, 2022 |
May 13, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 6, 2022 |
As filed with the Securities and Exchange Commission on May 6, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 6, 2022 Registration No. |
|
| May 6, 2022 |
Exhibit 4.3 KINIKSA PHARMACEUTICALS, LTD. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Es |
|
| May 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Kiniksa Pharmaceuticals, Ltd. |
|
| May 6, 2022 |
As filed with the Securities and Exchange Commission on May 6, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 6, 2022 Registration No. |
|
| May 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Kiniksa Pharmaceuticals, Ltd. |
|
| May 5, 2022 |
Non-Employee Director Compensation Program Exhibit 10.1 Kiniksa Pharmaceuticals, Ltd. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Kiniksa Pharmaceuticals, Ltd. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended, this “Program”). The cash and equity compensation described in this Program shall be |
|
| May 5, 2022 |
Exhibit 10.3 COLLABORATION AND LICENSE AGREEMENT by and between Kiniksa Pharmaceuticals (UK), Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Dated as of February 21, 2022 [**] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(a)(6) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv). Suc |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 5, 2022 |
Exhibit 10.2 COLLABORATION AND LICENSE AGREEMENT by and between Kiniksa Pharmaceuticals (UK), Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Dated as of February 21, 2022 [**] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(a)(6) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv). Suc |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or organiz |
|
| May 3, 2022 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update ? ARCALYST? (rilonacept) net revenue of $22.2 million in Q1 2022 ? ? ARCALYST full-year 2022 net revenue expected to be $115 - $130 million ? ? Cash reserves expected to fund operations into at least 2024 ? ? Conference call and webcast scheduled for 8:30 am ET today ? HAMILTON, BERMUDA |
|
| April 28, 2022 |
DEF 14A 1 tm223497-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 24, 2022 |
Exhibit 10.38 ? ? ? ? EXCLUSIVE LICENSE AGREEMENT ? by and between ? ? ? The Beth Israel Deaconess Medical Center and Primatope Therapeutics Inc. ? ? ? dated as of November 1, 2013 ? [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly |
|
| February 24, 2022 |
? Exhibit 10.36 ? EMPLOYMENT AGREEMENT ? This Employment Agreement (this ?Agreement?) is effective as of April 1, 2021 (the ?Effective Date?), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the ?Company?), and Arian Pano (the ?Employee?). ? WHEREAS, the operations of the Company and its Affiliates (as defined below) are a complex matter requiring direction and leadership in |
|
| February 24, 2022 |
Exhibit 10.33 ? CHANGE IN CONTROL AGREEMENT ? This Change in Control Agreement (this ?Agreement?) is made and entered into as of January 3, 2022 (the ?Effective Date?), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the ?Company?), and Michael Megna (the ?Employee?). ? WHEREAS, the Company recognizes that the possibility of a change in control of the Parent and a related inv |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
Exhibit 10.35 ? [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(a)(6). ? February 1, 2022 ? Ross Moat [***] ? Dear Ross, ? Reference is made to that certain Employment Agreement, dated on or about the date hereof, by and between Kiniksa Pharmaceuticals (UK), Ltd. (?Kiniksa UK?) and you (the ?Employment Agreement?). Kiniksa Pharmaceuticals, Ltd. (th |
|
| February 24, 2022 |
Exhibit 10.34 ? [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(a)(6). ? ? ? DATED February 1, 2022 ? ? ? (1) KINIKSA PHARMACEUTICALS (UK), LTD. ? ? (2) ROSS MOAT EMPLOYMENT AGREEMENT ? ? ? ? 1 KI.1177.0003\17379262v6 14 February 2022 ? CONTENTS Page 1DEFINITIONS AND INTERPRETATION?3 2Employment capacity?6 3COMMENCEMENT AND CONTINUITY OF EMPLOYMENT |
|
| February 24, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables S-8 (Form Type) Kiniksa Pharmaceuticals, Ltd. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common shares, par val |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 24, 2022 |
Exhibit 10.37 ? ? [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(a)(6). ? ? ? January 31, 2022 ? By Email ? Arian Pano [***] ? Dear Arian: ? The purpose of this letter agreement (?Agreement?) is to confirm the terms of your separation from Kiniksa Pharmaceuticals Corp. (?Kiniksa? or the ?Company?).1 Unless you rescind your assent as set forth in S |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or o |
|
| February 22, 2022 |
Exhibit 99.2 Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration ? Collaboration includes rights to develop and commercialize ARCALYST? and mavrilimumab in the Asia Pacific Region (excluding Japan) ? ? Kiniksa to receive $22 million upfront; eligible to receive development and commercial milestone payments and tiered royalties ? HAMILTON, BERMUDA ? February 22, 2022 ? Kin |
|
| February 22, 2022 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update ? ARCALYST? (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021 ? ? ARCALYST collaboration achieved profitability in Q4 2021 ? ? ARCALYST full-year 2022 net revenue expected to be $115 - $130 million ? ? Strategic collaboration with Huadong Medic |
|
| February 14, 2022 |
Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser ? Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. Investment Adviser ? Columbia Wanger Asset Management, LL |
|
| February 14, 2022 |
to Schedule 13G Joint Filing Agreement Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2022 in connection with their beneficial ownership of Kiniksa Pharmaceuticals, Ltd. |
|
| February 14, 2022 |
KNSA / Kiniksa Pharmaceuticals Ltd / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #2 Under the Securities and Exchange Act of 1934 Kiniksa Pharmaceuticals, Ltd (Name of Issuer) Class A Common Stock (Title of Class of Securities) G5269C101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 10, 2022 |
KNSA / Kiniksa Pharmaceuticals Ltd / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Kiniksa Pharmaceuticals Ltd. Class A Title of Class of Securities: Common Stock CUSIP Number: G5269C101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 10, 2022 |
KNSA / Kiniksa Pharmaceuticals Ltd / PICTET ASSET MANAGEMENT SA - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kiniksa Pharmaceuticals Ltd (Name of Issuer) COMMON STOCK (Title of Class of Securities) G5269C101 (CUSIP Number) 12/31/2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| January 10, 2022 |
Exhibit 99.1 Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones - ARCALYST? full-year 2022 guidance to be provided with Q4 2021 financial results - - Vixarelimab Phase 2b data in prurigo nodularis expected in 2H 2022 ? - KPL-404 Phase 2 trial in rheumatoid arthritis now enrolling and dosing patients - - Year-end 2021 cash reserves expected to fund current operating plan int |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation) (Com |
|
| January 3, 2022 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ?Agreement?) is made and entered into as of January 3, 2022 (the ?Effective Date?), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the ?Company?), and Eben Tessari (the ?Employee?). WHEREAS, the operations of the Company and its Affiliates (as defined below) are a comp |
|
| January 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or org |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 1, 2021 |
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution - Q3 2021 ARCALYST? (rilonacept) net revenue of $12.1 million - - ARCALYST prescribed by more than 200 physicians for recurrent pericarditis since approval - - Data from Phase 3 trial of mavrilimumab in COVID-19-related ARDS expected in Q1 2022 - - Data from Phase 2b trial of vixarelima |
|
| November 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or or |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 3, 2021 |
Exhibit 99.1 Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity - Q2 2021 ARCALYST? (rilonacept) net revenue of $7.7 million with greater than 100 prescribing physicians - - Phase 3 data from mavrilimumab clinical trial in COVID-19-related ARDS on-track for Q1 2022; new Phase 2 data demonstrate persistent clinical effect through Day 90 - - Initiation |
|
| August 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or orga |
|
| July 6, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation) (Commis |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or organiz |
|
| May 6, 2021 |
Non-Employee Director Compensation Program Exhibit 10.4 Kiniksa Pharmaceuticals, Ltd. ? Non-Employee Director Compensation Program ? Non-employee members of the board of directors (the ?Board?) of Kiniksa Pharmaceuticals, Ltd. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended effective as of April 9, 2021, this ?Program?). The cash and equity compensation |
|
| May 6, 2021 |
Exhibit 10.2 AMENDMENT NO. 1 ? THIS AMENDMENT NO. 1 (?Amendment No. 1?) to that certain License Agreement dated as of September 25, 2017 (the ?Original Agreement?) by and between Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company and having an address at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (?Kiniksa?), and Regeneron Pharmaceuticals, Inc., a corporation organized under |
|
| May 6, 2021 |
Employment Agreement, effective as of April 1, 2021, by and between the Company and Mark Ragosa Exhibit 10.3 EMPLOYMENT AGREEMENT ? This Employment Agreement (this ?Agreement?) is effective as of April 1, 2021 (the ?Effective Date?), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the ?Company?), and Mark Ragosa (the ?Employee?). WHEREAS, the operations of the Company and its Affiliates (as defined below) are a complex matter requiring direction and leadership in a vari |
|
| May 6, 2021 |
Exhibit 10.1 ? ? COMMERCIAL SUPPLY AGREEMENT ? ? ? This Commercial Supply Agreement (including Exhibit 1 hereto, this ?Agreement?) is entered into as of February 26, 2021 (the ?Effective Date?) by and between: ? Kiniksa Pharmaceuticals (UK), Ltd., a company incorporated under the laws of England and Wales having its registered office at Third Floor, 23 Old Bond Street, London W1S 4PZ, England (?KI |
|
| May 6, 2021 |
Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 4, 2021 |
Exhibit 99.1 Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity - ARCALYST? (rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis - - Mavrilimumab Phase 2 severe COVID-19 data demonstrated a reduction in mechanical ventilation and death at Day 29; Phase 3 enrollment ongoing - - Final KPL-404 Phase 1 data support fu |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or organiz |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549? SCHEDULE 14A (Rule 14a-101)? INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2021 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or orga |
|
| April 28, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549? SCHEDULE 14A (Rule 14a-101)? INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 3, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or organ |
|
| February 25, 2021 |
Offering Document under the 2018 Employee Share Purchase Plan (effective January 1, 2021) ? Exhibit 10.23 ? KINIKSA PHARMACEUTICALS, LTD. 2018 Employee SHARe Purchase Plan ? OFFERING DOCUMENT ? This document (this ?Offering Document?) is adopted by the Compensation Committee of the Board of Directors of Kiniksa Pharmaceuticals, Ltd. (the ?Company?), in its capacity as Administrator of the Kiniksa Pharmaceuticals, Ltd. 2018 Employee Share Purchase Plan (the ?Plan?) and is made a part of |
|
| February 25, 2021 |
As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 25, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| February 25, 2021 |
Exhibit 10.34 KINIKSA PHARMACEUTICALS, LTD. ? Restricted Stock Agreement AGREEMENT made this 18 day of September, 2015, between Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the "Company"), and Thomas Beetham (the "Founder"). ? For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows: 1.Purchase of Shares. ? The Company shall allot and issue to |
|
| February 25, 2021 |
Offering Document under the 2018 Employee Share Purchase Plan (effective July 1, 2019) Exhibit 10.22 ? KINIKSA PHARMACEUTICALS, LTD. 2018 Employee SHARe Purchase Plan ? OFFERING DOCUMENT ? This document (this ?Offering Document?) is adopted by the Compensation Committee of the Board of Directors of Kiniksa Pharmaceuticals, Ltd. (the ?Company?), in its capacity as Administrator of the Kiniksa Pharmaceuticals, Ltd. 2018 Employee Share Purchase Plan (the ?Plan?) and is made a part of t |
|
| February 25, 2021 |
? Exhibit 10.33 ? AMENDED AND RESTATED EMPLOYMENT AGREEMENT ? This Amended and Restated Employment Agreement (this ?Agreement?) is made and entered into as of May 29, 2018, 2018 (the ?Effective Date?), by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation (the ?Company?), and Thomas W. Beetham (the ?Employee?). WHEREAS, the operations of the Company and its Affiliates (as defined be |
|
| February 25, 2021 |
Subsidiaries of the Registrant ? Exhibit 21.1 SUBSIDIARIES OF KINIKSA PHARMACEUTICALS, LTD. ? The following subsidiaries are owned directly or indirectly by Kiniksa Pharmaceuticals, Ltd. Legal Name of Subsidiary Jurisdiction of Organization Kiniksa Pharmaceuticals Corp. Delaware Kiniksa Pharmaceuticals (France) SARL France Kiniksa Pharmaceuticals (Germany) GmbH Germany Kiniksa Pharmaceuticals GmbH Switzerland Kiniksa Pharmaceut |
|
| February 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or o |
|
| February 23, 2021 |
Exhibit 99.1 Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity - Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 - - Rilonacept in recurrent pericarditis granted priority review, with PDUFA goal date of March 21, 2021 - - Clinical data expected in 1H 2021 from KPL-404 (anti-CD40) |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kiniksa Pharmaceuticals, Ltd. (Name of Issuer) Class A Common Shares, par value $0.000273235 per share (Title of Class of Securities) G5269C101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to desi |
|
| February 12, 2021 |
EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. Investment Adviser – Columbia Wanger Asset Manage |
|
| February 12, 2021 |
to Schedule 13G Joint Filing Agreement EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 12, 2021 in connection with their beneficial ownership of Kiniksa Pharmaceuticals, Ltd. Each of Columbia Acorn Fund, Columbia Wanger Asset Management, LLC and Columbia Management Investment Advisers, LLC authorizes Ameriprise F |
|
| February 12, 2021 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 Kiniksa Pharmaceuticals, Ltd (Name of Issuer) Class A Common Stock (Title of Class of Securities) G5269C101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Kiniksa Pharmaceuticals Ltd. Class A Title of Class of Securities: Common Stock CUSIP Number: G5269C101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Sch |
|
| January 11, 2021 |
Exhibit 99.1 Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones - PDUFA goal date of March 21, 2021 for rilonacept in recurrent pericarditis - - Data from Phase 2 portion of mavrilimumab Phase 2/3 trial in severe COVID-19 pneumonia and hyperinflammation expected in 1H 2021 - - Final Phase 1 KPL-404 data expected in 1H 2021 - HAMILTON, BERMUDA – January 11, 2021 – Kiniksa Pharmace |
|
| January 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or or |
|
| December 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or o |
|
| November 10, 2020 |
Exhibit 10.1 RECOGNITION AND ATTORNMENT AGREEMENT AND AMENDMENT OF SUBLEASE RECOGNITION AND ATTORNMENT AGREEMENT AND AMENDMENT OF SUBLEASE (the “Agreement”) made as of the 6th day of November, 2020, by and between 92 HAYDEN AVENUE TRUST, as landlord (“Landlord”), and KINIKSA PHARMACEUTICALS CORP., a Delaware corporation, as tenant (interchangeably called “Kiniksa” or “Tenant”). R E C I T A L S By |
|
| November 10, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2020 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or or |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or or |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kiniksa Pharmaceuticals, Ltd. (Name of Issuer) Class A common shares, par value $0.000273235 per share (Title of Class of Securities) G5269C101 (CUSIP Number) October 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 5, 2020 |
Exhibit 99.1 Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity - Rilonacept commercial launch in recurrent pericarditis anticipated in 1H 2021, if approved by the FDA - Mavrilimumab Phase 2 trial in GCA achieved primary and secondary efficacy endpoints with statistical significance - All cohorts have been dosed in the KPL-404 (anti-CD40) Pha |
|
| October 26, 2020 |
Exhibit 99.1 Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020 - Mavrilimumab reduced time-to-flare and increased sustained remission in Phase 2 giant cell arteritis clinical trial - Primary and secondary efficacy endpoints achieved statistical significance - |
|
| October 26, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2020 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or or |
|
| September 17, 2020 |
September 17, 2020 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 8, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 8, 2020 Registration No. |
|
| August 4, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July, 30, 2020 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or orga |
|
| July 30, 2020 |
Exhibit 99.1 Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity - Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all major secondary efficacy endpoints; sBLA submission expected this year - Mavrilimumab global Phase 2/3 adaptive design trial in severe COVID-19 pneumonia and hyperinflam |
|
| July 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July, 25, 2020 Kiniksa Pharmaceuticals, Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-730430 98-1327726 (State or other jurisdiction of incorporation or orga |
|
| July 28, 2020 |
Exhibit 99.1 SUBSCRIPTION AGREEMENT This subscription agreement (this “Subscription Agreement”) is made as of July 21, 2020, by and among the Investors identified on the signature pages hereto (“Investors”), and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (the “Company”), and the parties hereto agree as follows: 1. Subscription. (a) The Company has authorized the sale and issuance to |
|
| July 28, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| July 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2020 Kiniksa Pharmaceuticals, Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-730430 98-1327726 (State or Other Jurisdiction (Commission (IRS Employer |
